3',5'-AnhydrothymidineCAS# 7481-90-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 7481-90-5 | SDF | Download SDF |
| PubChem ID | 264088 | Appearance | Powder |
| Formula | C10H12N2O4 | M.Wt | 224 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-(4,7-dioxabicyclo[3.2.0]heptan-3-yl)-5-methylpyrimidine-2,4-dione | ||
| SMILES | CC1=CN(C(=O)NC1=O)C2CC3C(O2)CO3 | ||
| Standard InChIKey | OAWLMYIJZBBZTP-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H12N2O4/c1-5-3-12(10(14)11-9(5)13)8-2-6-7(16-8)4-15-6/h3,6-8H,2,4H2,1H3,(H,11,13,14) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
3',5'-Anhydrothymidine Dilution Calculator
3',5'-Anhydrothymidine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4643 mL | 22.3214 mL | 44.6429 mL | 89.2857 mL | 111.6071 mL |
| 5 mM | 0.8929 mL | 4.4643 mL | 8.9286 mL | 17.8571 mL | 22.3214 mL |
| 10 mM | 0.4464 mL | 2.2321 mL | 4.4643 mL | 8.9286 mL | 11.1607 mL |
| 50 mM | 0.0893 mL | 0.4464 mL | 0.8929 mL | 1.7857 mL | 2.2321 mL |
| 100 mM | 0.0446 mL | 0.2232 mL | 0.4464 mL | 0.8929 mL | 1.1161 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Zalcitabine
Catalog No.:BCC5026
CAS No.:7481-89-2
- Methylophiopogonanone A
Catalog No.:BCN5417
CAS No.:74805-92-8
- Methylophiopogonanone B
Catalog No.:BCN5418
CAS No.:74805-91-7
- Methylophiopogonone A
Catalog No.:BCN2841
CAS No.:74805-90-6
- Methylophiopogonone B
Catalog No.:BCN8182
CAS No.:74805-89-3
- Ciglitazone
Catalog No.:BCC7014
CAS No.:74772-77-3
- VER-50589
Catalog No.:BCC5296
CAS No.:747413-08-7
- AUY922 (NVP-AUY922)
Catalog No.:BCC2123
CAS No.:747412-49-3
- Pterolactone A
Catalog No.:BCN6513
CAS No.:74730-10-2
- Secoxyloganin methyl ester
Catalog No.:BCN4299
CAS No.:74713-15-8
- Zaltoprofen
Catalog No.:BCC4442
CAS No.:74711-43-6
- 5-Hydroxyxanthotoxin
Catalog No.:BCC8107
CAS No.:7471-73-0
- GRP (porcine)
Catalog No.:BCC5809
CAS No.:74815-57-9
- Boc-Hyp-Ome
Catalog No.:BCC3252
CAS No.:74844-91-0
- Argatroban
Catalog No.:BCC3723
CAS No.:74863-84-6
- alpha-Carotene
Catalog No.:BCN3880
CAS No.:7488-99-5
- Vernakalant Hydrochloride
Catalog No.:BCC2037
CAS No.:748810-28-8
- 5-Carboxamidotryptamine maleate
Catalog No.:BCC6652
CAS No.:74885-72-6
- 5-Acetoxymatairesinol dimethyl ether
Catalog No.:BCN4300
CAS No.:74892-45-8
- Piracetam
Catalog No.:BCC4824
CAS No.:7491-74-9
- DMAT
Catalog No.:BCC1533
CAS No.:749234-11-5
- Allyl phenoxyacetate
Catalog No.:BCC8813
CAS No.:7493-74-5
- NSC 405020
Catalog No.:BCC2120
CAS No.:7497-07-6
- 2-((1,1-Dioxidotetrahydrothiophen-3-yl)(methyl)amino)-2-oxoethyl 3-(3-nitrophenyl)acrylate
Catalog No.:BCC6185
CAS No.:749872-43-3
High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine.[Pubmed:8863284]
J Pharm Sci. 1996 Aug;85(8):890-2.
A high-performance liquid chromatographic assay was developed and validated for a simulataneous determination of 2'-fluoro-2' 3'-dideoxyadenosine (FddA) and its metabolite, 2'-fluoro-2',3'-dideoxyinosine (Fddl) in dog plasma and urine. In vitro, FddA and Fddl exhibit activity against human immunodeficiency virus (HIV). A solid phase extraction was applied to extract FddA, Fddl, and the internal standard (IS; 3',5'-anhydrothymidine) from the biomatrices. The processed samples were chromatographed using a C8 column coupled with a mobile phase consisting of monobasic phosphate, dibasic phosphate, ethylene glycol monomethyl ether, and water. Detection was performed at 257 nm. The nominal retention times were 9, 14, and 26 min for Fddl, IS, and FddA, respectively. The lower limits of quantitation were 0.1 and 2.0 micrograms/mL in plasma and urine, respectively, for both analytes. The accuracy of the assay deviated < or = 10% from the nominal concentrations, and the precision was < or = 14% coefficient of variation. In either matrix, both analytes were stable for at least three freeze-thaw cycles and in the injection media for at least 54 h. The extraction recoveries of the analytes were greater than 80%. The application of this assay was demonstrated in a preliminary pharmacokinetic study of FddA and Fddl in dogs. Two male dogs per dose level received a 100, 250, or 500 mg/kg oral dose of FddA once daily for 14 days. The early appearance of Fddl in plasma (0.25 h; the first sampling time) and greater plasma levels of Fddl than FddA (> 50-fold of Cmax), suggested that the conversion of FddA to Fddl was rapid and extensive. Renal excretion appeared to be the major route of elimination of Fddl.
